Reduced insulin use and diabetes complications upon introduction of SGLT-2 inhibitors and GLP1-receptor agonists in low- and middle-income countries: A microsimulation

Open Access

Peer-reviewed

Research Article

Global Health & Population Project on Access to Care for Cardiometabolic Diseases (HPACC)

Reader Comments (0)

Insulin
Is the Subject Area "Insulin" applicable to this article?

Thanks for your feedback.
Diabetes mellitus
Is the Subject Area "Diabetes mellitus" applicable to this article?

Thanks for your feedback.
Low and middle income countries
Is the Subject Area "Low and middle income countries" applicable to this article?

Thanks for your feedback.
Hypoglycemia
Is the Subject Area "Hypoglycemia" applicable to this article?

Thanks for your feedback.
Type 2 diabetes risk
Is the Subject Area "Type 2 diabetes risk" applicable to this article?

Thanks for your feedback.
Cardiology
Is the Subject Area "Cardiology" applicable to this article?

Thanks for your feedback.
Type 2 diabetes
Is the Subject Area "Type 2 diabetes" applicable to this article?

Thanks for your feedback.
Cardiovascular disease risk
Is the Subject Area "Cardiovascular disease risk" applicable to this article?

Thanks for your feedback.